Literature DB >> 25766563

A "RANning" leap with "XPOrt" into TKI resistance.

Feyruz Rassool1, Danilo Perrotti1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25766563      PMCID： PMC4357578          DOI： 10.1182/blood-2015-01-622217

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

2.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

3.  shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Authors:  Jamshid S Khorashad; Anna M Eiring; Clinton C Mason; Kevin C Gantz; Amber D Bowler; Hannah M Redwine; Fan Yu; Ira L Kraft; Anthony D Pomicter; Kimberly R Reynolds; Anthony J Iovino; Matthew S Zabriskie; William L Heaton; Srinivas K Tantravahi; Michael Kauffman; Sharon Shacham; Alex Chenchik; Kyle Bonneau; Katharine S Ullman; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

4.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

5.  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Authors:  Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2013-04-16       Impact factor: 11.528

Review 6.  Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.

Authors:  David S P Tan; Philippe L Bedard; John Kuruvilla; Lillian L Siu; Albiruni R Abdul Razak
Journal:  Cancer Discov       Date:  2014-04-17       Impact factor: 39.397

7.  Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

Authors:  Nicholas B Heaney; Francesca Pellicano; Bin Zhang; Lisa Crawford; Su Chu; Syed M A Kazmi; Elaine K Allan; Heather G Jorgensen; Alexandra E Irvine; Ravi Bhatia; Tessa L Holyoake
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

8.  Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

Authors:  Kensuke Kojima; Steven M Kornblau; Vivian Ruvolo; Archana Dilip; Seshagiri Duvvuri; R Eric Davis; Min Zhang; Zhiqiang Wang; Kevin R Coombes; Nianxiang Zhang; Yi Hua Qiu; Jared K Burks; Hagop Kantarjian; Sharon Shacham; Michael Kauffman; Michael Andreeff
Journal:  Blood       Date:  2013-04-05       Impact factor: 22.113

Review 9.  Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Hagop M Kantarjian; Jorge E Cortes
Journal:  Cancer Control       Date:  2009-04       Impact factor: 3.302

10.  Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Authors:  Christopher J Walker; Joshua J Oaks; Ramasamy Santhanam; Paolo Neviani; Jason G Harb; Gregory Ferenchak; Justin J Ellis; Yosef Landesman; Ann-Kathrin Eisfeld; Nash Y Gabrail; Carrie L Smith; Michael A Caligiuri; Peter Hokland; Denis Claude Roy; Alistair Reid; Dragana Milojkovic; John M Goldman; Jane Apperley; Ramiro Garzon; Guido Marcucci; Sharon Shacham; Michael G Kauffman; Danilo Perrotti
Journal:  Blood       Date:  2013-08-22       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.